Sequoia Capital Invests Hundreds of Millions in Hong Kong Asia Medical Group

Recently, HongShan invested hundreds of millions of yuan in China’s largest chain of specialized cardiovascular hospitals—Hong Kong Asia Medical Holdings Limited (hereinafter referred to as “Hong Kong Asia Medical”) aims to accelerate the expansion of its domestic and international businesses through close collaboration between both parties, thereby establishing itself as the most successful specialized hospital management group brand in China.

Cardiovascular disease is one of the most prevalent chronic diseases in China, with over 290 million patients, creating a substantial demand for specialized medical services. As the largest chain of cardiovascular specialty hospitals in China, Asia Medical Group, headquartered in Hong Kong, operates multiple specialized institutions, including Wuhan Asia Heart Hospital (one of the largest cardiac specialty hospitals in China), Xinjiang Yaxin Cardiovascular Hospital, and Wuhan Jiangcheng Yaxin Hospital (under construction), with a total bed capacity approaching 3,000.

It is understood that Wuhan Asia Heart Hospital, under Hong Kong Asia Healthcare, is the third-largest cardiovascular specialty hospital in China (with Beijing Fuwai Hospital and Anzhen Hospital ranking first and second, respectively). Its volume of cardiac surgical procedures ranks third nationwide, while its volume of interventional cardiology procedures ranks among the top ten in China.

For many years, Hong Kong Asia Healthcare has consistently adhered to its core philosophy of “patient-centric care,” establishing a premier medical service platform for China’s leading cardiovascular disease diagnosis and treatment experts. Meanwhile, through models such as entrusted management and co-construction, Hong Kong Asia Healthcare maintains close collaborations with multiple Grade 3A hospitals, including the Department of Cardiovascular Surgery at The First Affiliated Hospital of Shantou University, exporting its advanced healthcare management concepts and high-end medical service talent.

Mr. Xie Junming, Chairman of Hong Kong Asia Medical Holdings Limited, stated, “Over the past seventeen years, Hong Kong Asia Medical has operated with diligence and dedication in China’s healthcare industry, earning the trust of patients, support from the government, and recognition from peers. Today, we are forming a close, comprehensive strategic alliance with Sequoia Capital. We believe that, built on the foundation of ‘respect, understanding, trust, and support,’ this partnership will undoubtedly propel Hong Kong Asia Medical to new heights, enabling us to deliver high-quality medical services that are appropriate, safe, attentive, and reasonably priced to more patients!”

While securing hundreds of millions in investment from HongShan, Asia Medical Group (Hong Kong) aims to leverage the combined resource advantages of both parties and work collaboratively with partners to elevate the diagnosis and treatment standards for cardiovascular diseases in China, thereby improving the healthcare experience for the vast number of patients suffering from these conditions.

Neil Shen, Global Executive Partner at Sequoia Capital, stated: “The healthcare sector has always been a key investment focus for HongShan, particularly the medical services segment. Sequoia Capital highly recognizes the team behind Asia Medical Group in Hong Kong. With nearly two decades of dedicated expertise in this industry, they have grown into a leading cardiovascular specialty hospital chain in China, boasting a solid business foundation and delivering high-quality medical services to a broad patient base.”

HongShan (formerly Sequoia Capital China) was founded in 2005 and has consistently ranked among the top firms in China’s venture capital and private equity (VC/PE) sector. Currently, HongShan manages funds totaling nearly RMB 50 billion. Over the past decade, HongShan has stayed attuned to economic trends, focusing on four key sectors: technology/media, healthcare, consumer goods/services, and new energy/clean technology/advanced manufacturing. It has invested in more than 500 high-growth companies characterized by distinct technological advantages, innovative business models, and strong potential for growth and returns. These portfolio companies include many well-known domestic enterprises such as Alibaba, Vipshop, Sina, JD.com, Ourpalm, Qihoo 360, Jumei, Dianping, Meituan, Toutiao, AutoNavi, Ganji, DJI, Noah Wealth Management, Wanda Cinemas, Deppon Logistics, ZTO Express, BETA Pharma, Snibe Co., Ltd., and BGI Genomics.

It is reported that HongShan China Fund adheres to value investing and currently holds a portfolio of nearly 50 companies in the healthcare sector, covering multiple sub-sectors including pharmaceuticals, medical devices, healthcare service groups, and mobile health.